17 results about "Immunophenotyping" patented technology

Described herein are methods, systems, and programming for determining a tumor immunophenotype of an image of a tumor. Some embodiments include dividing an image into tiles depicting tumor epithelium and / or tumor stroma. For each tile, an epithelium-immune cell density and a stroma-immune cell density may be calculated based on a number of immune cells identified in the tumor epithelium and the tumor stroma, respectively. Based on the epithelium-immune cell density and the stroma-immune cell density, an inflammation type of the type may be determined, and a tumor immunophenotype may be determined based on each tile's inflammation type.

Compositions and methods for treating inflammation associated with Farber disease in a subject in need thereof by administering to the subject a pharmaceutical composition comprising a recombinant human acid ceramidase in a therapeutically effective amount of about 0.1 mg / kg to about 50 mg / kg to inhibit inflammation and / or to inhibit or reduce pro-inflammatory potential of neutrophils and / or monocytes in the subject.

The invention relates to an acute leukemia (ALL) high-throughput flow cytometry kit, and belongs to the field of leukemia detection.16 ALL cell antigens are added on the basis of an original 8-color flow cytometry, 24 antigens in the same cell can be detected at the same time, the detection precision of minimal residual focus (MRD) is greatly improved, and the detection sensitivity is improved. The ALL cells are divided into 12 developmental stages, so that immunological typing during primary diagnosis and immunophenotype variation after bone marrow transplantation and CAR-T cell treatment can be more accurately recognized, and the method has very important guiding significance on evaluation of treatment effects of patients and adjustment of treatment schemes.

Method and systems for sorting potential hematopoietic stem cell transplant (HSCT) donors as a donor or non-donor using immunophenotyping of blood samples. The methods and systems can be used to identify a donor for a HSCT or to choose a donor to generate a HSCT blood product that is not likely to result in bad outcomes for a recipient. Also provided herein are methods and systems for training machine learning models that can be used in methods and systems for sorting potential HSCT donors.

The application provides a bladder cancer immunophenotyping recognition method and system, comprising: preprocessing pathological image data to obtain preprocessed pathological image data; constructing a tumor and stroma region segmentation model based on a semantic segmentation network TransUNet, training the tumor and stroma region segmentation model using the preprocessed pathological image data and label data, and obtaining a trained tumor and stroma region segmentation model; constructing a TIL recognition neural network model classification model based on Resnet50 using a tumor and stroma segmentation result output by the trained tumor and stroma region segmentation model; and obtaining a bladder cancer immunophenotyping result based on a lymphocyte infiltration score output by the TIL recognition neural network model classification model. The application automatically recognizes a tumor region and immune cell distribution using digital pathological images, constructs a standardized immunoscore and typing method, and improves the individual decision-making ability of clinical immunotherapy.

The invention relates to a method for predicting the evolution of an immune response in a subject towards an effector or suppressor response, based on cellular plasticity determined by the cytokine milieu generated after antigenic stimulation. The invention also allows for evaluating the generation of antigen-specific memory regulatory T cells in the evolution of the immune response. The invention also relates to a kit for carrying out the method according to the invention.

[0006] Methods and systems for generating an immune profile for a subject are described. Optionally, the methods include contacting at least a first aliquot of a sample from the subject with at least a first immunophenotyping panel to fluorescently label cells contained in the sample; processing the fluorescently labeled cells using a full-spectrum flow cytometer to generate fluorescence intensity data or derived data for the fluorescently labeled cells from the sample; providing at least a subset of the fluorescence intensity data or derived data for the fluorescently labeled cells as input to an ensemble machine learning model configured to process the data and classify individual cells as belonging to one of a plurality of distinct immune cell subpopulations; and outputting a total cell number or cell frequency for each of a plurality of distinct immune cell subpopulations in the sample as part of the immune profile for the subject.

A microfluidic device for particle analysis, such as immunophenotyping, includes a plurality of microfluidic channels for the passage of a particle-laden fluid flow, a plurality of dedicated impedance sensors for generating impedance signals relative to each microfluidic sensor. The impedance sensors are CODES Coulter sensors, each having a distinct coded sequence for generating mutually orthogonal signals. The system uses a multi-frequency excitation signal for driving the Coulter sensors, such that the Coulter sensors generate multi-frequency impedance signals. The system outputs the multi-frequency signals of the plurality of impedance sensors as a single multi-frequency multiplexed signal, which is subsequently separated into a plurality of single-frequency multiplexed signals, which are then demodulated into single-frequency component signals corresponding to each of the Coulter sensors.

Provided herein are compositions comprising protein encapsulated nanoparticles, and methods of making said compositions. In an aspect, provided herein are compositions comprising cytokine encapsulated nanoparticles, and methods of making said compositions. Further provided herein are methods of monitoring an immunophenotype of a subject and associated immunodiagnostic assays and immunodiagnostic compositions.

The present application relates to a kind of acute leukemia (ALL) high flux flow detection kit, belong to leukemia detection field, the present application is based on the original 8 color flow to increase 16 kinds of ALL cell antigen, can realize the simultaneous detection of 24 kinds of antigens in the same cell, not only greatly improve the detection precision of micro residual lesion (MRD), and by being divided into 12 development stages to ALL cell, can more accurately identify immunotyping when first diagnosis, and immunophenotypic aberration after bone marrow transplantation and after CAR-T cell therapy, this has very important guiding significance to the evaluation of patient treatment effect and the adjustment of treatment scheme.

This application discloses a combination of gene markers for predicting ovarian cancer prognosis, immunotherapy response, or immunophenotype, and their applications, belonging to the field of molecular diagnostic technology for ovarian cancer. The combination of gene markers includes... MMP1 , GJB2 , PLPP4 , MME , GREM1 , COL10A1 , CTHRC1 , CEMIP , MMP11 and NTM The combination of gene markers presented in this application can not only predict the prognostic risk of ovarian cancer, but also predict the immunotherapy response and immunophenotype of ovarian cancer samples, with excellent performance.

The present invention relates to a reagent panels for the measurement of minimal residual disease (MRD) associated with pediatric B-cell precursor acute lymphoblastic leukemia (B- ALL) by multiparametric flow cytometry. The reagent panel of the invention comprises a combination of antibodies directed against markers, wherein the combination of antibodies comprises i) antibodies targeting markers CD45, CD20, CD34, CD38, CD10, CD58, CD66c, CD73, CD81, CD123, CD304, CD44, CD86, CD99 and CD371, and ii) antibodies targeting markers CD19 and / or CD22, wherein the antibodies are conjugated with fluorochromes. The invention further relates to the use of said panels for detecting MRD associated with B-ALL and / or for identifying a subject at risk of developing B-ALL relapse. The invention also relates to methods of detecting MRD associated with B-ALL. Key advantages of the invention include achieving high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity.

Method and systems for sorting potential hematopoietic stem cell transplant (HSCT) donors as a donor or non-donor using immunophenotyping of blood samples. The methods and systems can be used to identify a donor for a HSCT or to choose a donor to generate a HSCT blood product that is not likely to result in bad outcomes for a recipient. Also provided herein are methods and systems for training machine learning models that can be used in methods and systems for sorting potential HSCT donors.

Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

Method and systems for generating an immune profile for a subject are described. In some instances, the methods comprise contacting at least a first aliquot of a sample from the subject with at least a first immunophenotyping panel to fluorescently-label cells contained within the sample; processing the fluorescently-labeled cells using a full spectrum flow cytometer to generate fluorescence intensity data, or data derived therefrom, for fluorescently-labeled cells from the sample; providing at least a subset of the fluorescence intensity data, or data derived therefrom, for the fluorescently-labeled cells as input to an ensemble machine learning model configured to process the data and classify individual cells as belonging to one of a plurality of distinct immune cell sub-populations; and outputting a total cell count or cell frequency for each of the plurality of distinct immune cell sub-populations in the sample as part of an immune profile for the subject.

Methods of identifying an immunophenotype for a tumour are described, using one or more whole slide images of a sample of the tumour that has been stained using at least a CD8 label Related methods and systems are also described.

Screening methods are provided that are based on using ELISpot assays to measure the distribution profile of maximum spot intensity or mean spot intensity of spontaneous cytokine or chemokine or the number of "low intensity" spontaneous cytokine or chemokine producing cells as a clinically relevant measure of immune function for diagnosing patients with a particular disorder based on one or more of these measurements and for treating the particular disorder in the patient. In some embodiments, the cytokine is IFN-gamma or TNF-alpha. Patients can optionally be further evaluated to determine whether they are of an immunosuppressed or hyperinflammatory immune phenotype by quantifying cytokine and / or chemokine levels in a biological sample. Representative disorders include sepsis, autoimmune disease, autoimmunity, cancer, and lymphopenia.